1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

BREAKING NEWS: Mesothelioma Trial Results Show No Improvement in Overall Survival

Researcher

Recent mesothelioma drug trials for CBP501 showed little improvements in the survival rates of patients with malignant mesothelioma.

In the July 5, 2014 edition of Lung Cancer, Dr. Lee Krug of Memorial Sloan Kettering Cancer Center, who was the lead investigator of the CBP501 trial, reported that the trial was found not to improve overall survival in patients with malignant mesothelioma.

CBP 501 is a drug in that interrupts DNA repair of transformed cells. It was thought to add synergy to the combination of our first line therapy.

Cisplatin/pemetrexed coupled with a placebo or CBP501, at first glance, appeared to hold promise, having met their endpoint of progression-free survival at 4 months. However, in further evaluation, it was found not to increase overall survival or response rate.

Though we are disappointed to learn of these results, the science from this study nonetheless adds to our knowledge of this disease. We are grateful to all volunteers who participated, because only through a clinical trial are we able to learn what works and what doesn’t.

Read the abstract here. http://www.lungcancerjournal.info/article/S0169-5002(14)00266-9/abstract

Also...

In Other News

Clinical Trials

Mesothelioma is one of the rarest cancers so there are always clinical trials going on to advance research efforts. This session presents on four different

Read More »

Peritoneal Surgery/HIPEC

Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC).  This session

Read More »

Share:

Facebook
Twitter
LinkedIn